Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker
| Autor: | Eloisa Bonfa, Milton Ruiz Alves, Nadia E. Aikawa, Ruth Miyuki Santo, Ana Cristina Medeiros-Ribeiro, Karina Bonfiglioli, Priscila Novaes, Fany Solange Usuba |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Cell biology medicine.medical_specialty Population lcsh:Medicine Arthritis Diseases Gastroenterology Article Arthritis Rheumatoid 03 medical and health sciences Medical research 0302 clinical medicine Rheumatology Internal medicine medicine Humans Ocular Surface Disease Index Prospective Studies Signs and symptoms lcsh:Science Prospective cohort study education education.field_of_study Goblet cell Multidisciplinary business.industry lcsh:R Health care Case-control study Middle Aged medicine.disease 030104 developmental biology medicine.anatomical_structure Case-Control Studies Rheumatoid arthritis Biomarker (medicine) Dry Eye Syndromes Female Tumor Necrosis Factor Inhibitors lcsh:Q Goblet Cells business Conjunctiva Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-020-70944-9 |
| Popis: | Dry eye disease (DED) is common in Rheumatoid Arthritis (RA) patients. The application of conjunctival goblet cell count as a clinical biomarker to diagnose and respond to treatment can take place in rheumatoid arthritis patients under TNF-inhibitors (TNFi) therapy. This study aimed to investigate the ocular surface parameters and the long-term effects of TNFi therapy on ocular surface features and goblet cell count of rheumatoid arthritis patients. At baseline, rheumatoid arthritis patients eligible to TNFi were compared to healthy controls (similar age/gender), regarding Ocular Surface Disease Index (OSDI) questionnaire, Schirmer I test, tear break-up time test, vital dye staining of the ocular surface, and conjunctival impression cytology. DED severity grade, impression cytology score, and goblet cell count were analyzed. Rheumatoid arthritis patients were followed after three (3 M) and 12 months (12 M), during TNFi treatment. Sixteen rheumatoid arthritis patients and 24 controls were compared: a higher frequency of abnormal OSDI (68.8% vs. 16.7%, p = 0.002), Schirmer’s test p = 0.042), meibomian gland dysfunction (50% vs. 8.3%, p = 0.007), abnormal impression cytology (75% vs. 8.3%, p p 2 vs. 742 (562–863) cells/mm2, p = 0.004]. The presence of Meibomian gland dysfunction was associated with higher disease activity scores (p p = 0.001], and an improvement in impression cytology score [1 (0.5–2) vs. 1 (0–1), p = 0.031] and in goblet cell count [325 (274–707) vs. 931 (656–1,244), p p = 0.047]. Multifactorial DED is frequent in RA patients, comprising aqueous, lipid, and mucin components. TNFi prompt improves tear production and recovers the goblet cells, which can be a biomarker of the pathological process and response to therapy in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|